• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一名老年EGFR突变型肺癌合并肺结核患者的奥希替尼与抗结核治疗联合应用：病例报告

Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report.

作者信息

Matsuura Hiroaki, Higo Hisao, Kuribayashi Tadahiro, Tamaoki Akihiko, Nakasuka Takamasa, Uno Mari, Makimoto Go, Ninomiya Kiichiro, Fujii Masanori, Rai Kammei, Ichihara Eiki, Hotta Katsuyuki, Miyahara Nobuaki, Tabata Masahiro, Maeda Yoshinobu, Kiura Katsuyuki, Ohashi Kadoaki

机构信息

Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.

Okayama Health Foundation Hospital, Okayama Health Foundation, Okayama, Japan.

出版信息

Thorac Cancer. 2024 Jun;15(17):1390-1394. doi: 10.1111/1759-7714.15324. Epub 2024 May 2.

DOI:10.1111/1759-7714.15324
PMID:38698706
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11168902/
Abstract

The concurrent incidence of lung cancer and tuberculosis is expected to escalate due to the projected growth in the older population. Combination therapy with osimertinib and antituberculosis drugs has not been well-established. We report a case of successful treatment involving the concomitant administration of osimertinib and antituberculosis drugs in an older patient, an 89-year-old female, diagnosed with epidermal growth factor receptor (EGFR)-mutant lung cancer and pulmonary tuberculosis. Accumulating evidence is warranted to develop an optimal treatment strategy for patients with lung cancer and tuberculosis.

摘要

由于老年人口预计会增长，肺癌和肺结核的并发率预计将会上升。奥希替尼与抗结核药物的联合治疗尚未得到充分确立。我们报告了一例成功治疗的病例，一名89岁女性老年患者同时接受了奥希替尼和抗结核药物治疗，该患者被诊断为表皮生长因子受体（EGFR）突变型肺癌和肺结核。有必要积累证据，为肺癌合并肺结核患者制定最佳治疗策略。

相似文献

1
Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report.一名老年EGFR突变型肺癌合并肺结核患者的奥希替尼与抗结核治疗联合应用：病例报告
Thorac Cancer. 2024 Jun;15(17):1390-1394. doi: 10.1111/1759-7714.15324. Epub 2024 May 2.
2
Efficacy of osimertinib resumption with dabrafenib and trametinib for elderly patients with EGFR-mutated lung adenocarcinoma harboring acquired BRAF V600E resistant mutation resistant to osimertinib.奥希替尼联合达拉非尼和曲美替尼对携带获得性BRAF V600E耐药突变且对奥希替尼耐药的EGFR突变型老年肺腺癌患者的疗效。
Jpn J Clin Oncol. 2025 Jul 6;55(7):832-836. doi: 10.1093/jjco/hyaf059.
3
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.辅助性表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）用于治疗已切除的Ⅰ至Ⅲ期非小细胞肺癌且伴有EGFR突变的患者。
Cochrane Database Syst Rev. 2025 May 27;5(5):CD015140. doi: 10.1002/14651858.CD015140.pub2.
4
FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation.液体衰减反转恢复序列（FLAIR）：一项II期开放标签随机研究，比较奥希替尼联合贝伐单抗与奥希替尼用于初治的携带EGFR 21L858R突变的复发或转移性非小细胞肺癌患者。
Clin Lung Cancer. 2025 Mar;26(2):152-157.e1. doi: 10.1016/j.cllc.2024.09.002. Epub 2024 Sep 20.
5
Risk Factors Associated with Suboptimal Real-World Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Front-Line Recommended Therapy.表皮生长因子受体（EGFR）突变的非小细胞肺癌患者接受一线推荐治疗后，与欠佳的真实世界治疗结果相关的风险因素
Adv Ther. 2025 May 29. doi: 10.1007/s12325-025-03234-3.
6
First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case Report.一线奥希替尼治疗表皮生长因子受体（EGFR）突变的肺鳞状细胞癌：病例报告
Cancer Rep (Hoboken). 2025 Jul;8(7):e70273. doi: 10.1002/cnr2.70273.
7
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve -Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).一项关于奥希替尼联合或不联合雷莫西尤单抗用于酪氨酸激酶抑制剂初治的EGFR突变转移性非小细胞肺癌的多中心开放标签随机II期研究（RAMOSE试验）。
J Clin Oncol. 2025 Feb;43(4):403-411. doi: 10.1200/JCO.24.00533. Epub 2024 Oct 8.
8
Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA.根据循环肿瘤DNA中的基线基因改变，奥希替尼在初治的表皮生长因子受体（EGFR）突变非小细胞肺癌中的阶段特异性疗效。
Invest New Drugs. 2025 Feb;43(1):101-107. doi: 10.1007/s10637-024-01500-9. Epub 2025 Jan 9.
9
Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study.奥希替尼联合化疗与奥希替尼治疗伴有EGFR和TP53突变的晚期非小细胞肺癌患者的前瞻性队列研究
Sci Rep. 2025 Jul 1;15(1):20952. doi: 10.1038/s41598-025-03422-9.
10
Co-occurrence of interstitial lung disease and pulmonary embolism as adverse events of adjuvant osimertinib treatment for EGFR mutant non-small cell lung cancer: a case report.间质肺疾病与肺栓塞并存作为表皮生长因子受体（EGFR）突变的非小细胞肺癌辅助奥希替尼治疗的不良事件：一例报告
BMC Pulm Med. 2025 Jul 3;25(1):311. doi: 10.1186/s12890-025-03787-7.

本文引用的文献

1
Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor.合并肺结核会影响接受表皮生长因子受体（EGFR）酪氨酸激酶抑制剂治疗的晚期EGFR突变型肺腺癌患者的生存。
Cancer Manag Res. 2021 Oct 1;13:7517-7526. doi: 10.2147/CMAR.S326349. eCollection 2021.
2
Population aging and trends of pulmonary tuberculosis incidence in the elderly.人口老龄化与老年人肺结核发病率趋势
BMC Infect Dis. 2021 Mar 25;21(1):302. doi: 10.1186/s12879-021-05994-z.
3
Factors associated with false negative interferon-γ release assay results in patients with tuberculosis: A systematic review with meta-analysis.
与结核病患者干扰素-γ释放试验假阴性结果相关的因素：系统评价与荟萃分析。
Sci Rep. 2020 Jan 31;10(1):1607. doi: 10.1038/s41598-020-58459-9.
4
Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review.奥希替尼诱导的机化性肺炎型间质性肺疾病中奥希替尼的成功再次给药：一例报告及文献综述
Intern Med. 2020 Mar 15;59(6):823-828. doi: 10.2169/internalmedicine.3689-19. Epub 2019 Nov 29.
5
The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse.恶性肿瘤患者结核负担：发病率、死亡率和复发率。
Sci Rep. 2019 Aug 15;9(1):11901. doi: 10.1038/s41598-019-48395-8.
6
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.伊曲康唑和利福平对奥希替尼药代动力学的影响。
Br J Clin Pharmacol. 2018 Jun;84(6):1156-1169. doi: 10.1111/bcp.13534. Epub 2018 Mar 23.
7
A case of tuberculosis reactivation suspected of cancer progression during oral tyrosine kinase inhibitor treatment in a patient diagnosed as non-small cell lung cancer.一名被诊断为非小细胞肺癌的患者在口服酪氨酸激酶抑制剂治疗期间，出现疑似癌症进展的结核复发病例。
J Thorac Dis. 2017 Aug;9(8):E709-E713. doi: 10.21037/jtd.2017.07.31.
8
The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.潜伏性结核感染的全球负担：使用数学模型的重新估计
PLoS Med. 2016 Oct 25;13(10):e1002152. doi: 10.1371/journal.pmed.1002152. eCollection 2016 Oct.
9
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.阿法替尼的临床药代动力学与药效学
Clin Pharmacokinet. 2017 Mar;56(3):235-250. doi: 10.1007/s40262-016-0440-1.
10
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.阿法替尼治疗表皮生长因子受体抑制剂耐药的非小细胞肺癌
N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.